Tianjin Pharmaceutical announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for histidine approved and issued by the State Drug Administration. The API complies with the relevant requirements for drug registration, has been approved for registration, and can be sold domestically. The company submitted an application for listing registration in November 2024 and was accepted, and supplementary information was submitted from December 2025 to March 2026. Up to now, the company has invested about 1.47 million yuan in R&D in the histidine API project.
Zhitongcaijing · 1d ago
Share
Listen to the news
Tianjin Pharmaceutical announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for histidine approved and issued by the State Drug Administration. The API complies with the relevant requirements for drug registration, has been approved for registration, and can be sold domestically. The company submitted an application for listing registration in November 2024 and was accepted, and supplementary information was submitted from December 2025 to March 2026. Up to now, the company has invested about 1.47 million yuan in R&D in the histidine API project.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending